KDOQI (Kidney Disease Outcomes Quality Initiative)


NKF KDOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis |
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | Cardiovascular Disease in Dialysis Patients | History of KDOQI |

KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients


Tables

Table A. Cardiovascular Mortality in Pediatric CKD Stage 5

Table B. Autopsy Studies of Cardiac Pathology in Pediatric CKD Stage 5

Table C. Prevalence of Cardiovascular Risk Factors in Pediatic CKD Stage 5

Table 1. Comparison of Surgical Interventions for CAD To Prevent Future Cardiovascular Outcomes

Table 2. Effect of Tissue versus Nontissue Valve Replacement on Prevention of Future Cardiovascular Outcomes

Table 3. Presence of Systolic Dysfunction on Echocardiogram as a Predictor of Future CVD Outcomes

Table 4. Increased LV Mass Index on Echocardiogram as a Predictor of Future Cardiovascular Outcomes

Table 5. Dosage Adjustments and Drugs To Be Avoided

Table 6. AHA Guidelines for the Prevention, Screening and Evaluation, and Treatment of Stroke, with KDOQI Modifications

Table 7. Association of Low Ankle-Arm Brachial Index with Risk of Cardiovascular Outcomes

Table 8. Oral Hypoglycemic Agents Contraindicated or to be used with Caution in Dialysis Patients

Table 9. Antihypertensive Agents Contraindicated or to be used with Caution in Dialysis Patients

Table 10. Removal of Antihypertensive Drugs with Dialysis

Table 11. Factors Implicated in the Pathogenesis of Hypertension in Dialysis Patients

Table 12. Antihypertensive Drug Therapy in Dialysis: Guidelines for Selection

Table 13. Causes of Resistant Hypertension in Dialysis Patients

Table 14. Association of Current Smoking with Risk of Cardiovascular Outcomes

Table 15. Psychometric Testing Instruments

Table 16. Association of Low Serum Calcium Level with Risk of Cardiovascular Outcomes and Markers

Table 17. Association of Elevated Serum Calcium-Phosphorus Product with Risk of Cardiovascular Outcomes and Markers

Table 18. Association of Elevated Serum Phosphorus Level with Risk of Cardiovascular Outcomes and Markers

Table 19. Association of Serum PTH Level with Risk of Cardiovascular Outcomes and Markers

Table 20. Factors Related to IDH Treatment

Table 21. Association of Elevated Random Troponin I Levels with Risk of Cardiovascular Outcomes

Table 22. Association of Elevated Random Troponin T Levels with Risk of Cardiovascular Outcomes

Table 23. Association of Elevated Serum CRP Level with Risk of Cardiovascular Outcomes and Markers

Table 24. Markers That Could Be Used To Assess Oxidative Stress in CKD

Table 25. Potential Effects of ω-3 Fatty Acids on CVD Risk Factors

Table 26. Summary of Effects of Fatty Acid Types on Lipid Classes

Table 27. Amount of ω-3 Fatty Acids Provided by Selected Food Sources and Supplements

Table 28. Alpha-Linolenic Acid (LNA) and Potassium (K+) Content of Selected Foods per 100 g

Table 29. Association of the Lp(a) Concentration with Risk of CVD or Markers

Table 30. Association of the apo(a) Polymorphism with Risk of CVD or Markers

Table 31. Factors Contributing to Wasting in CKD Patients

Table 32. Factors That May Affect Serum Albumin Levels in CKD Patients

Table 33. Assessment of Wasting in CKD Patients

Table 34. Association of SGA Score >1 with Risk of Cardiovascular Outcomes and Markers

Table 35. Approximate Definition of Categories of Family History in the General Population

Table 36. Association of the MTHFR 677C→T Polymorphism with Risk of Prevalent CVD or Markers

Table 37. Association of the ApoE Polymorphism with Risk of CVD or Markers

Table 38. Association of the ACE Polymorphism with Risk of CVD or Markers

Table 39. Example of Format for Summary Tables

Table 40. Format for Guidelines

Table 41. Rating the Strength of Guideline Recommendations

Table 42. Rating the Strength of the Evidence